Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

被引：7
|
作者：
Elsbernd, Paul M. [1 ]
Carter, Jonathan L. [1 ]
机构：
[1] Mayo Clin, Dept Neurol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2021年 / 15卷
关键词：
monoclonal antibodies; multiple sclerosis; relapsing; progressive; review; NATALIZUMAB ANTIBODIES; INTERFERON BETA-1A; CONTROLLED TRIAL; RISK; ALEMTUZUMAB; RITUXIMAB; OCRELIZUMAB; PLACEBO; MECHANISMS; SAFETY;
D O I：
10.2147/BTT.S267273
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence leading to their approval, and clinically relevant considerations for each of the current monoclonal antibody therapies approved for the treatment of multiple sclerosis.
引用
收藏
页码：255 / 263
页数：9
相关论文
共 50 条
  • [41] Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives
    D'Amico, Emanuele
    Caserta, Cinzia
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (03) : 251 - 268
  • [42] Minimal Breastmilk Transfer of Rituximab, A Monoclonal Antibody Used In Multiple Sclerosis
    Krysko, K. M.
    Lahue, S. C.
    Anderson, A.
    Rutatangwa, A.
    Rowles, W.
    Schubert, R. D.
    Marcus, J.
    Riley, C. S.
    Bevan, C.
    Hale, T. W.
    Bove, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 147 - 147
  • [43] Monoclonal antibody therapy in multiple sclerosis Paradigm shifts and emerging challenges
    Fontoura, Paulo
    MABS, 2010, 2 (06) : 670 - 681
  • [44] HUMANIZATION OF A MOUSE MONOCLONAL-ANTIBODY FOR THE TREATMENT OF MULTIPLE-SCLEROSIS
    LEGER, OJ
    KEEN, S
    SALDANHA, J
    JONES, ST
    BENDIG, MM
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 192 - 192
  • [45] Monoclonal antibody therapies and neurologic disorders
    Novak, John C.
    Lovett-Racke, Amy E.
    Racke, Michael K.
    ARCHIVES OF NEUROLOGY, 2008, 65 (09) : 1162 - 1165
  • [46] Monoclonal antibody-based therapies
    Shima, Midori
    HEMASPHERE, 2018, 2 : 182 - 184
  • [47] Monoclonal antibody therapies in transfusion medicine
    Ouwehand, WH
    Watkins, NA
    Garner, SF
    Smethurst, PA
    VOX SANGUINIS, 2004, 87 : 151 - 154
  • [48] Monoclonal Antibody Therapies against Anthrax
    Chen, Zhaochun
    Moayeri, Mahtab
    Purcell, Robert
    TOXINS, 2011, 3 (08): : 1004 - 1019
  • [49] Monoclonal antibody therapies for solid tumors
    Tassev, Dimiter V.
    Cheung, Nai-Kong V.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (03) : 341 - 353
  • [50] Measuring the impact of monoclonal antibody therapies
    Lim, Ka Keat
    Ng, Kenrick
    Balachandran, Sathiyaa
    Russell, Mark D.
    Boalch, Amy
    Sinclair, Alasdair
    Coker, Bolaji
    Vinnakota, Krishna
    Mansoor, Rashid
    Douiri, Abdel
    Marks, Lara V.
    Sacks, Steven
    FRONTIERS IN MEDICINE, 2023, 10
12345